{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:32:50Z","timestamp":1784064770369,"version":"3.55.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejphar.2024.176928","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T22:03:29Z","timestamp":1724450609000},"page":"176928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines"],"prefix":"10.1016","volume":"982","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176928_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ckj\/sfx105","article-title":"Low-dose rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience","volume":"11","author":"Bagchi","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejphar.2024.176928_bib2","first-page":"350","article-title":"Bortezomib as a novel approach to early rcurrent membranous glomerulonephritis after kidney transplant refractory to combined conventional rituximab therapy","volume":"15","author":"Barbari","year":"2017","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.ejphar.2024.176928_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.176928_bib4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2024.176928_bib5","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib6","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1517\/13543784.9.9.2017","article-title":"Immunoadsorption, current status and future developments","volume":"9","author":"Braun","year":"2005","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2024.176928_bib7","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fc\u03b3 receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2024.176928_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ckj\/sfad041","article-title":"Future landscape for the management of membranous nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejphar.2024.176928_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI83840","article-title":"Rituximab does not reset defective early B cell tolerance checkpoints","volume":"126","author":"Chamberlain","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2024.176928_bib11","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","article-title":"Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome","volume":"12","author":"Chan","year":"2007","journal-title":"Nephrology"},{"key":"10.1016\/j.ejphar.2024.176928_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4274\/balkanmedj.galenos.2023.2022-9-7","article-title":"Combination of rituximab and low-dose tacrolimus in the treatment of refractory membranous nephropathy: a retrospective cohort study","volume":"40","author":"Chen","year":"2023","journal-title":"Balkan Med. J."},{"key":"10.1016\/j.ejphar.2024.176928_bib13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/0886022X.2022.2073892","article-title":"Therapeutic apheresis in kidney diseases: an updated review","volume":"44","author":"Chen","year":"2022","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ejphar.2024.176928_bib14","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3346\/jkms.2018.33.e74","article-title":"The effect of mycophenolate mofetil versus cyclosporine as combination therapy with low dose corticosteroids in high-risk patients with idiopathic membranous nephropathy: a multicenter randomized trial","volume":"33","author":"Choi","year":"2018","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.ejphar.2024.176928_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00467-023-06085-8","article-title":"A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance","volume":"39","author":"Conversano","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12882-017-0459-z","article-title":"Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series","volume":"18","author":"Cortazar","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","article-title":"Immunopathogenesis of membranous nephropathy: an update","volume":"36","author":"Debiec","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejphar.2024.176928_bib19","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2024.176928_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","article-title":"Update on the application of monoclonal antibody therapy in primary membranous nephropathy","volume":"83","author":"Deng","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2024.176928_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15314","article-title":"Engineered clearing agents for the selective depletion of antigen-specific antibodies","volume":"8","author":"Devanaboyina","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.176928_bib22","first-page":"706","article-title":"A novel approach to rapid induction of remission in primary membranous nephropathy","volume":"93","author":"Dobronravov","year":"2021","journal-title":"Ter. Arkh."},{"key":"10.1016\/j.ejphar.2024.176928_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ndt\/gfad156","article-title":"Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial","volume":"39","author":"Duan","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2024.176928_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.ejphar.2024.176928_bib25","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1681\/ASN.V1092014","article-title":"Effect of protein a immunoadsorption in nephrotic syndrome of various etiologies","volume":"10","author":"Esnault","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40620-020-00781-6","article-title":"Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy","volume":"34","author":"Fenoglio","year":"2020","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2024.176928_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000515087","article-title":"Bortezomib treatment for refractory pLA2R-positive membranous nephropathy","volume":"1","author":"Geara","year":"2021","journal-title":"Glomerular Dis."},{"key":"10.1016\/j.ejphar.2024.176928_bib29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2024.176928_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","article-title":"Chronic administration of belimumab, a bLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects","volume":"91","author":"Halpern","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejphar.2024.176928_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jca.21949","article-title":"Peptide GAM immunoadsorption in anti\u2010PLA2R positive autoimmune membranous nephropathy. The PRISM trial","volume":"37","author":"Hamilton","year":"2021","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.ejphar.2024.176928_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jca.21599","article-title":"Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti\u2010PLA2R positive primary membranous nephropathy","volume":"33","author":"Hamilton","year":"2017","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.ejphar.2024.176928_bib33","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.18632\/oncotarget.23232","article-title":"BAFF and APRIL expression as an autoimmune signature of membranous nephropathy","volume":"9","author":"Han","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2024.176928_bib34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.ejphar.2024.176928_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","author":"Hartono","year":"2014","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.atherosclerosissup.2012.10.025","article-title":"Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients","volume":"14","author":"Heigl","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.ejphar.2024.176928_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2068213","article-title":"Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering","volume":"14","author":"Hori","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.ejphar.2024.176928_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000484717","article-title":"Changes in the spectrum of kidney diseases: an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China","volume":"4","author":"Hou","year":"2018","journal-title":"Kidney Dis."},{"key":"10.1016\/j.ejphar.2024.176928_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110317","article-title":"Membranous nephropathy: mechanistic insights and therapeutic perspectives","volume":"120","author":"Hua","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2024.176928_bib40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12392","article-title":"Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation","volume":"270","author":"Igawa","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2024.176928_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063236","article-title":"Engineered monoclonal antibody with novel antigen-sweeping activity in vivo","volume":"8","author":"Igawa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.176928_bib42","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00467-022-05786-w","article-title":"Mizoribine halts kidney fibrosis in childhood IgA nephropathy: association with modulation of M2-type macrophages","volume":"38","author":"Ikezumi","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejphar.2024.176928_bib44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/ijmr.IJMR_312_19","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences","volume":"155","author":"Jafarzadeh","year":"2022","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejphar.2024.176928_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.788830","article-title":"Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders","volume":"12","author":"Kaegi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib46","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ejphar.2024.176928_bib47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000123041","article-title":"FKBP family proteins: immunophilins with versatile biological functions","volume":"16","author":"Kang","year":"2008","journal-title":"Neurosignals"},{"key":"10.1016\/j.ejphar.2024.176928_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2024.176928_bib49","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","article-title":"The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border","volume":"79","author":"Kerjaschki","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2024.176928_bib50","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2024.176928_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae138","article-title":"A novel approach to induce early remission in high-risk primary membranous nephropathy","author":"Kochoyan","year":"2024","journal-title":"Nephrol Dial Transplant. gfae138"},{"key":"10.1016\/j.ejphar.2024.176928_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.822508","article-title":"Strategies towards antigen-specific treatments for membranous nephropathy","volume":"13","author":"K\u00f6llner","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2024.176928_bib54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jneuroim.2017.09.001","article-title":"Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis","volume":"312","author":"Lazaridis","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib55","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2024.176928_bib56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.intimp.2019.03.002","article-title":"Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: a pairwise and network meta-analysis","volume":"70","author":"Liu","year":"2019","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2024.176928_bib57","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.176928_bib58","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose\u2010escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2024.176928_bib59","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1007\/s10238-023-01183-1","article-title":"Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A(2) receptor antibody positive idiopathic membranous nephropathy","volume":"23","author":"Ma","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejphar.2024.176928_bib60","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3109\/0886022X.2013.808133","article-title":"Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria","volume":"35","author":"Matsumoto","year":"2013","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ejphar.2024.176928_bib61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4161\/mabs.23452","article-title":"Novel asymmetrically engineered antibody Fc variant with superior Fc\u03b3R binding affinity and specificity compared with afucosylated Fc variant","volume":"5","author":"Mimoto","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.ejphar.2024.176928_bib62","first-page":"1691","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2024.176928_bib63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.176928_bib64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/jpm14030249","article-title":"Is There a place for apheresis in the management of idiopathic membranous nephropathy? a report of three cases and literature review","volume":"14","author":"Naciri Bennani","year":"2024","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejphar.2024.176928_bib65","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ekir.2023.01.035","article-title":"Obinutuzumab in refractory phospholipase A2 receptor-associated membranous nephropathy with severe CKD","volume":"8","author":"Naik","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ejphar.2024.176928_bib66","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1681\/ASN.2006070732","article-title":"Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance","volume":"18","author":"Nakajo","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s13730-022-00715-0","article-title":"Fanconi syndrome in an elderly patient with membranous nephropathy during treatment with the immunosuppressant mizoribine","volume":"12","author":"Nishikawa","year":"2022","journal-title":"CEN Case Reports"},{"key":"10.1016\/j.ejphar.2024.176928_bib68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.transci.2017.08.013","article-title":"Immunoadsorption in neurological disorders","volume":"56","author":"Oji","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.ejphar.2024.176928_bib69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pa.19.040179.001143","article-title":"Mechanisms of glucocorticoid action on immune processes","volume":"19","author":"Parrillo","year":"1979","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2024.176928_bib70","doi-asserted-by":"crossref","first-page":"336","DOI":"10.34067\/KID.0004672020","article-title":"Low-dose rituximab monotherapy or in combination with tacrolimus is effective in primary membranous nephropathy","volume":"2","author":"Pathak","year":"2021","journal-title":"Kidney"},{"key":"10.1016\/j.ejphar.2024.176928_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.666971","volume":"12","author":"Piantoni","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176928_bib72","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2024.176928_bib73","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib74","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejphar.2024.176928_bib75","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2024.176928_bib76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-020117-043811","article-title":"Molecular pathogenesis of membranous nephropathy","volume":"15","author":"Ronco","year":"2020","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejphar.2024.176928_bib77","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib78","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603237","article-title":"Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment?","volume":"11","author":"Sadeqi Nezhad","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.909503","article-title":"Post-transplant thrombotic microangiopathy due to a pathogenic mutation in complement factor I in a patient with membranous nephropathy: sase report and review of literature","volume":"13","author":"Saleem","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib81","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy","volume":"100","author":"Salhi","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2024.176928_bib82","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib83","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","volume":"35","author":"Savage","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2024.176928_bib84","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-1-4939-8648-4_21","article-title":"Fc Engineering: tailored synthetic human IgG1-Fc repertoire for high-affinity interaction with FcRn at pH 6.0","volume":"1827","author":"Saxena","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2024.176928_bib85","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40620-020-00874-2","article-title":"Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab","volume":"34","author":"Schmidt","year":"2020","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib86","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2024.176928_bib87","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ki.1991.242","article-title":"Elevated urinary excretion of the C5b-9 complex in membranous nephropathy","volume":"40","author":"Schulze","year":"1991","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2024.176928_bib88","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2024.176928_bib89","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.ejphar.2024.176928_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1009864","article-title":"The role of the complement system in primary membranous nephropathy: a narrative review in the era of new therapeutic targets","volume":"13","author":"So","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib91","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.semnephrol.2017.05.020","article-title":"Immunoadsorption in autoimmune diseases affecting the kidney","volume":"37","author":"Stummvoll","year":"2017","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102931","article-title":"Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases","volume":"21","author":"Su","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2024.176928_bib93","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ymthe.2020.11.017","article-title":"Selective depletion of antigen-specific antibodies for the treatment of demyelinating Disease","volume":"29","author":"Sun","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2024.176928_bib94","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11427-022-2212-5","article-title":"CARs: a new approach for the treatment of autoimmune diseases","volume":"66","author":"Sun","year":"2022","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejphar.2024.176928_bib95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/bbrc.2000.3104","article-title":"Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein","volume":"274","author":"Takahashi","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2024.176928_bib96","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri856","article-title":"Roles of Fc receptors in autoimmunity","volume":"2","author":"Takai","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib97","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2024.176928_bib98","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib100","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1172\/JCI115101","article-title":"Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine","volume":"87","author":"Turka","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2024.176928_bib101","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2024.176928_bib102","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib103","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood-2014-07-585976","article-title":"Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers","volume":"124","author":"Wallin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2024.176928_bib104","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.12998\/wjcc.v11.i22.5309","article-title":"Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: a case report","volume":"11","author":"Wang","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ejphar.2024.176928_bib105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12882-023-03206-1","article-title":"Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib106","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lfs.2016.04.012","article-title":"Treatment of membranous nephropathy with mizoribine: a control trial","volume":"154","author":"Wang","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2024.176928_bib107","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10157-022-02304-y","article-title":"Mizoribine combined with steroids and dietary sodium restriction on the treatment of primary membranous nephropathy: a prospective study","volume":"27","author":"Wang","year":"2023","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib108","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s11255-020-02680-y","article-title":"Effect of mizoribine pulse therapy in adult membranous nephropathy","volume":"53","author":"Wang","year":"2020","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.ejphar.2024.176928_bib109","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4103\/0366-6999.178967","article-title":"Remission of refractory membranous nephropathy by low-dose rituximab: a case report","volume":"129","author":"Wang","year":"2016","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejphar.2024.176928_bib110","doi-asserted-by":"crossref","first-page":"566","DOI":"10.12998\/wjcc.v11.i3.566","article-title":"Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: a single-center experience","volume":"11","author":"Wang","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ejphar.2024.176928_bib111","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib112","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2019.05.021","article-title":"Treatment of membranous nephropathy in patients with THSD7A antibodies using immunoadsorption","volume":"74","author":"Weinmann-Menke","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2024.176928_bib113","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/19420862.2017.1359455","article-title":"Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn","volume":"9","author":"Yang","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ejphar.2024.176928_bib114","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1523-1755.2000.00168.x","article-title":"A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome","volume":"58","author":"Yoshioka","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2024.176928_bib115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2024.176928_bib116","article-title":"Case report: successful treatment of refractory membranous nephropathy with telitacicept","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176928_bib117","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/0886022X.2022.2083517","article-title":"Changes in the spectrum of kidney diseases: a survey of 2803 patients from 2010 to 2018 at a single center in southeastern China","volume":"44","author":"Zheng","year":"2022","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ejphar.2024.176928_bib118","first-page":"7622","article-title":"Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study","volume":"13","author":"Zhu","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ejphar.2024.176928_bib119","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2024.176928_bib120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat. Rev. Nephrol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924006174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924006174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T23:05:26Z","timestamp":1726268726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924006174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":120,"alternative-id":["S0014299924006174"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176928","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176928"}}